Cempra Inc (NASDAQ:CEMP) was downgraded by equities researchers at Vetr from a “buy” rating to a “sell” rating in a note issued to investors on Monday. They currently have a $4.07 target price on the stock. Vetr‘s price objective indicates a potential downside of 3.10% from the stock’s current price.

Several other brokerages have also recently issued reports on CEMP. Morgan Stanley raised shares of Cempra from an “underweight” rating to an “equal weight” rating and set a $5.00 target price for the company in a report on Friday, December 30th. Stifel Nicolaus reissued a “hold” rating and set a $4.00 target price on shares of Cempra in a report on Wednesday, March 1st. Gabelli cut shares of Cempra from a “buy” rating to a “hold” rating in a report on Wednesday, November 23rd. Zacks Investment Research cut shares of Cempra from a “buy” rating to a “hold” rating in a report on Tuesday, February 28th. Finally, WBB Securities cut shares of Cempra from a “buy” rating to a “hold” rating and reduced their target price for the stock from $40.00 to $4.00 in a report on Thursday, December 29th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $11.88.

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Shares of Cempra (NASDAQ:CEMP) traded up 9.09% during mid-day trading on Monday, reaching $4.20. 1,974,747 shares of the company’s stock traded hands. The company’s 50 day moving average is $3.42 and its 200 day moving average is $10.73. Cempra has a 12-month low of $2.55 and a 12-month high of $26.95. The company’s market cap is $220.05 million.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/cempra-inc-cemp-stock-rating-lowered-by-vetr-inc.html

Cempra (NASDAQ:CEMP) last issued its earnings results on Tuesday, February 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. The business had revenue of $7.95 million for the quarter, compared to analysts’ expectations of $4.19 million. During the same period last year, the business earned ($0.48) EPS. The company’s revenue for the quarter was up 37.3% on a year-over-year basis. On average, analysts predict that Cempra will post ($1.17) EPS for the current fiscal year.

Your IP Address:

In other news, Director Dov A. Md Goldstein sold 937,600 shares of Cempra stock in a transaction dated Friday, January 6th. The shares were sold at an average price of $3.41, for a total value of $3,197,216.00. Following the sale, the director now owns 95 shares in the company, valued at $323.95. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dov A. Md Goldstein sold 150,000 shares of Cempra stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $3.55, for a total transaction of $532,500.00. Following the completion of the sale, the director now owns 95 shares in the company, valued at approximately $337.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,193,060 shares of company stock worth $4,088,280. Company insiders own 17.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new stake in shares of Cempra during the fourth quarter valued at about $111,000. Legal & General Group Plc raised its stake in shares of Cempra by 23.0% in the first quarter. Legal & General Group Plc now owns 6,711 shares of the company’s stock valued at $114,000 after buying an additional 1,256 shares during the period. Advisor Group Inc. raised its stake in shares of Cempra by 2,258.0% in the third quarter. Advisor Group Inc. now owns 6,508 shares of the company’s stock valued at $157,000 after buying an additional 6,232 shares during the period. Teton Advisors Inc. raised its stake in shares of Cempra by 133.3% in the fourth quarter. Teton Advisors Inc. now owns 70,000 shares of the company’s stock valued at $196,000 after buying an additional 40,000 shares during the period. Finally, BlackRock Group LTD raised its stake in shares of Cempra by 65.3% in the first quarter. BlackRock Group LTD now owns 13,145 shares of the company’s stock valued at $231,000 after buying an additional 5,193 shares during the period. Institutional investors and hedge funds own 79.92% of the company’s stock.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.

5 Day Chart for NASDAQ:CEMP

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.